Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GTI-2501. Lorus Therapeutics.

G C Tu1, X Tu

  • 1Department of Pathology, Cell Biology and Anatomy, Thomas Jefferson University, Philadelphia, PA 19107, USA. Guang-Chou.Tu@mail.tju.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|March 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The progression of basaltic-rhyolitic melt storage at Yellowstone Caldera.

Nature·2025
Same author

[Therapeutic mechanism of <i>Cynanchum wilfordii</i> for ulcerative colitis: an analysis using UPLC-QE-MS, network pharmacology and metabolomics].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2024
Same author

Composition analysis of 1,495 cases of upper urinary tract calculi: the role of age and gender.

European review for medical and pharmacological sciences·2024
Same author

Peritumoural MRI radiomics signature of brain metastases can predict epidermal growth factor receptor mutation status in lung adenocarcinoma.

Clinical radiology·2023
Same author

[Anti-inflammatory mechanism of <i>Balanophora involucrata</i>: a network pharmacology and molecular docking-based analysis and verification in lipopolysaccharide-induced RAW264.7 cells].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2023
Same author

Age and Sex Differences in the Association of Sleep Duration and Overweight/Obesity among Chinese Participants Age above 45 Years: A Cohort Study.

The journal of nutrition, health & aging·2022

GTI-2501, an anticancer drug targeting ribonucleotide reductase, showed effectiveness in preclinical cancer models. A Phase I trial is underway to evaluate its safety and efficacy in patients with refractory lymphomas and solid tumors.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lorus Therapeutics is developing GTI-2501, an antisense anticancer drug.
  • GTI-2501 targets the R1 component of ribonucleotide reductase.

Purpose of the Study:

  • To evaluate the safety and efficacy of GTI-2501 in cancer patients.

Main Methods:

  • A Phase I, dose-escalating clinical trial was initiated in the US.
  • The trial enrolled patients with refractory lymphomas or solid tumors.

Main Results:

  • Preclinical studies demonstrated GTI-2501's efficacy in various human cancer models.
  • The drug showed effectiveness against lung, breast, colon, kidney, ovary, pancreas, and skin cancer cell lines.

Conclusions:

Related Experiment Videos

  • GTI-2501 holds potential as an anticancer therapeutic.
  • Further clinical evaluation is warranted based on preclinical data.